Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)

Overview of attention for article published in The Lancet, September 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

news: 34 news outlets
blogs: 2 blogs
policy: 2 policy sources
twitter: 610 X users
patent: 5 patents

facebook: 1 Facebook page
reddit: 4 Redditors
video: 1 YouTube creator
podcasts: 2 podcasts

Readers on

mendeley: 262 Mendeley

So far, Altmetric has seen 664 X posts from 610 X users, with an upper bound of 4,610,712 followers.

@DrToddLee @kallmemeg @ThomRawson @dr_anne_cori There was some trial data but not clinical endpoints for rapid decision making then: https://t.co/dCBmyZaaqJ

RT @gjrossir: Olvidé adjuntar este hilo sobre la última campaña publicitaria del Minsa en favor de AstraZeneca, que inició el 1 de febrero…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 660 additional X posts.